Stephenv Liu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ARROS-1 Trial of Zidesamtinib Aims to Address Current TKI Limitations in ROS1+ NSCLC

ARROS-1 Trial of Zidesamtinib Aims to Address Current TKI Limitations in ROS1+ NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesGeorgetown universityDistrict of columbiaStephenv liuCrizotinib xalkoriEuropean organisation for researchNuvalent incNational cancer instituteAmerican association for cancer research symposiumGeorgetown lombardi comprehensive cancer centerDemonstrates early phase efficacyEuropean organisationAmerican associationCancer researchNorth americaHeart therapeutics

Dr Liu Previews ASCO 2024 Lung Cancer Data

Dr Liu Previews ASCO 2024 Lung Cancer Data
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Stephenv liuGeorgetown universityGeorgetown lombardi comprehensive cancer centerThoracic oncologyDevelopmental therapeutics

Dr Liu on the Ongoing Investigation of Zidesamtinib in ROS1+ Tumors

Stephen V. Liu, MD, discusses the potential benefits and ongoing investigation of zidesamtinib for patients with ROS1-positive tumors.

Stephenv liuGeorgetown universityGeorgetown lombardi comprehensive cancer centerThoracic oncologyDevelopmental therapeuticsLung cancerOs1 positive tumorsNvl 520

Taletrectinib Continues to Demonstrate High Clinical Activity in Advanced ROS1+ NSCLC

Clinicians discuss data on the ROS1 TKI taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

New yorkUnited statesJ thor oncChristine bestvinaStephenv liuAlexander drilonJason porterChina national medical products administrationCancer centerUniversity of chicago medicine comprehensive cancer centerGeorgetown universityNational medical products administration of chinaResearch instituteLung cancer disease research groupGeorgetown lombardi comprehensive cancer centerWest cancer center

Dr Liu on the Benefits of Biomarker Testing in NSCLC

Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.

Stephenv liuGeorgetown universityGeorgetown lombardi comprehensive cancer centerThoracic oncologyDevelopmental therapeuticsPer new york lung cancer symposiumLung cancer